41 related articles for article (PubMed ID: 20926993)
1. Pharmacokinetic-pharmacodynamic modeling of unboosted Atazanavir in a cohort of stable HIV-infected patients.
Goutelle S; Baudry T; Gagnieu MC; Boibieux A; Livrozet JM; Peyramond D; Chidiac C; Tod M; Ferry T;
Antimicrob Agents Chemother; 2013 Jan; 57(1):517-23. PubMed ID: 23147727
[TBL] [Abstract][Full Text] [Related]
2. Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.
Moyle G; Else L; Jackson A; Back D; Yapa MH; Seymour N; Ringner-Nackter L; Karolia Z; Gazzard B; Boffito M
Antimicrob Agents Chemother; 2013 Aug; 57(8):3640-4. PubMed ID: 23689708
[TBL] [Abstract][Full Text] [Related]
3. Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.
Hong Y; Kowalski KG; Zhang J; Zhu L; Horga M; Bertz R; Pfister M; Roy A
Antimicrob Agents Chemother; 2011 Dec; 55(12):5746-52. PubMed ID: 21930880
[TBL] [Abstract][Full Text] [Related]
4. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.
Siccardi M; D'Avolio A; Baietto L; Gibbons S; Sciandra M; Colucci D; Bonora S; Khoo S; Back DJ; Di Perri G; Owen A
Clin Infect Dis; 2008 Nov; 47(9):1222-5. PubMed ID: 18831695
[TBL] [Abstract][Full Text] [Related]
5. Raltegravir pharmacokinetics during pregnancy.
Watts DH; Stek A; Best BM; Wang J; Capparelli EV; Cressey TR; Aweeka F; Lizak P; Kreitchmann R; Burchett SK; Shapiro DE; Hawkins E; Smith E; Mirochnick M;
J Acquir Immune Defic Syndr; 2014 Dec; 67(4):375-81. PubMed ID: 25162818
[TBL] [Abstract][Full Text] [Related]
6. Effect of ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteers.
Blonk M; Colbers A; Poirters A; Schouwenberg B; Burger D
Antimicrob Agents Chemother; 2012 Oct; 56(10):5070-5. PubMed ID: 22802250
[TBL] [Abstract][Full Text] [Related]
7. A Genome-Wide Association Study Identifies a Candidate Gene Associated With Atazanavir Exposure Measured in Hair.
Tamraz B; Huang Y; French AL; Kassaye S; Anastos K; Nowicki MJ; Gange S; Gustafson DR; Bacchetti P; Greenblatt RM; Hysi PG; Aouizerat BE
Clin Pharmacol Ther; 2018 Nov; 104(5):949-956. PubMed ID: 29315502
[TBL] [Abstract][Full Text] [Related]
8. A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV.
Bukkems VE; Post TM; Colbers AP; Burger DM; Svensson EM
CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):161-172. PubMed ID: 33369217
[TBL] [Abstract][Full Text] [Related]
9. Drug-drug interaction of atazanavir on UGT1A1-mediated glucuronidation of molidustat in human.
van der Mey D; Gerisch M; Jungmann NA; Kaiser A; Yoshikawa K; Schulz S; Radtke M; Lentini S
Basic Clin Pharmacol Toxicol; 2021 Mar; 128(3):511-524. PubMed ID: 33232579
[TBL] [Abstract][Full Text] [Related]
10. Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.
Gantner P; Bani-Sadr F; Garraffo R; Roger PM; Treger M; Jovelin T; Pugliese P; Rey D;
PLoS One; 2016; 11(10):e0164240. PubMed ID: 27798641
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of raltegravir in the management of HIV infection.
Liedtke MD; Tomlin CR; Lockhart SM; Miller MM; Rathbun RC
Infect Drug Resist; 2014; 7():73-84. PubMed ID: 24672249
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.
Rathbun RC; Liedtke MD
Pharmaceutics; 2011 Oct; 3(4):745-81. PubMed ID: 24309307
[TBL] [Abstract][Full Text] [Related]
13. Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.
Focà E; Ripamonti D; Motta D; Torti C
Drugs; 2012 Jun; 72(9):1161-73. PubMed ID: 22646049
[TBL] [Abstract][Full Text] [Related]
14. Divalent metals and pH alter raltegravir disposition in vitro.
Moss DM; Siccardi M; Murphy M; Piperakis MM; Khoo SH; Back DJ; Owen A
Antimicrob Agents Chemother; 2012 Jun; 56(6):3020-6. PubMed ID: 22450971
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.
Arab-Alameddine M; Fayet-Mello A; Lubomirov R; Neely M; di Iulio J; Owen A; Boffito M; Cavassini M; Günthard HF; Rentsch K; Buclin T; Aouri M; Telenti A; Decosterd LA; Rotger M; Csajka C;
Antimicrob Agents Chemother; 2012 Jun; 56(6):2959-66. PubMed ID: 22371894
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy.
Ananworanich J; Gorowara M; Avihingsanon A; Kerr SJ; van Heesch N; Khongpetch C; Uanithirat A; Hill A; Ruxrungtham K; Burger DM;
Antimicrob Agents Chemother; 2012 Apr; 56(4):1892-8. PubMed ID: 22252825
[TBL] [Abstract][Full Text] [Related]
17. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Conti F; Clementi E
Ther Drug Monit; 2010 Dec; 32(6):782-6. PubMed ID: 20926993
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
Gantner P; Koeppel C; Partisani M; Batard ML; Bernard-Henry C; Cheneau C; De Mautort E; Priester M; Muret P; Sueur C; Fafi-Kremer S; Rey D
Scand J Infect Dis; 2014 Dec; 46(12):838-45. PubMed ID: 25229167
[TBL] [Abstract][Full Text] [Related]
19. Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.
Siccardi M; DʼAvolio A; Rodriguez-Novoa S; Cuenca L; Simiele M; Baietto L; Calcagno A; Moss D; Bonora S; Soriano V; Back DJ; Owen A; Di Perri G
Ther Drug Monit; 2012 Apr; 34(2):232-5. PubMed ID: 22406652
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
